vimarsana.com
Home
Live Updates
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrate
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrate
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients...
Related Keywords
United States ,
Philadelphia ,
Pennsylvania ,
United Kingdom ,
Canada ,
Julip Miller ,
Victor Moreno ,
Dana Lynch ,
National Cancer Institute Surveillance ,
United Newsfile Corp ,
Corporate Communications ,
Decision Resources Group ,
Exchange Commission ,
Foundation Inc ,
European Society For Medical Oncology ,
End Results Program ,
Corporate Affairs ,
Nasdaq ,
Clinical Research ,
Annual European Society ,
Medical Oncology ,
Elliot Norry ,
Chief Medical Officer ,
Independent Data Safety Monitoring ,
Resources Group ,
Forecast Aug ,
Cancer Institute Surveillance ,
Cancer Stat Facts ,
Keytruda Prescribing Information ,
Clin Oncol ,
Prescribing Information ,
Keytruda Prescribing ,
Opdivo Prescribing ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Senior Director ,
Markets ,